Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
CDW
Sha Tin, New Territories, Hong Kongcdw-holding.com.hk ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
CDW (through subsidiary ABio) is engaged in joint R&D on next-generation lipid nanoparticle delivery technologies for mRNA, antibody, and nucleic acid therapeutics; clinical results have not yet been announced, work is preclinical.
- Modalities
- AntibodyRecombinant proteinLipid nanoparticle delivery therapymRNA-based drugs
- Industry
- Biotech
02
Partnerships
Neoregen Biotech Co., Ltd.Premier (for CDW Healthcare US IT services, not biotech)
Beyond the preview
Go deeper on CDW.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CDW.